Transition to high-dose or strong opioids: a population-based study of people initiating opioids in Australia.
Adolescent
Adult
Aged
Aged, 80 and over
Analgesics, Opioid
/ administration & dosage
Australia
/ epidemiology
Cohort Studies
Dose-Response Relationship, Drug
Drug Prescriptions
/ statistics & numerical data
Female
Humans
Male
Middle Aged
Pain
/ drug therapy
Practice Patterns, Physicians'
/ statistics & numerical data
Retrospective Studies
Young Adult
Australia
dose escalation
drug utilization
high dose
opioid analgesics
strong opioids
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
05
06
2019
revised:
06
08
2019
accepted:
29
11
2019
pubmed:
10
12
2019
medline:
19
3
2021
entrez:
10
12
2019
Statut:
ppublish
Résumé
Strong and high-dose opioids are associated with opioid overdose and death. The objective of this study was to determine the rate and predictors of transitioning to high-dose or strong opioids among people initiating opioids. Retrospective cohort study. Australia. People initiating opioid analgesics from July 2013 to January 2018 were identified from a random 10% sample of Australia's Pharmaceutical Benefits Scheme eligible population. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for the predictors of escalating to ≥ 50 mg oral morphine equivalents (OMEs)/day (cohort 1); ≥ 90 mg OMEs/day (cohort 2) and transitioning from weak opioids to strong opioids (cohort 3) over 12 months of follow-up. Predictors included age, sex, number of comorbidities, history of depression, prior treatment for cancer and selected other medication use. In total, 861 691 people initiated opioids at average doses < 50 mg OMEs/day (cohort 1), 874 401 at < 90 mg OMEs/day (cohort 2) and 603 884 initiated weak opioids (cohort 3). Overall, 1.4% of people escalated to doses ≥ 50 mg OMEs/day, 0.8% to doses ≥ 90 mg OMEs/day and 7.3% transitioned to strong opioids. The strongest predictors of transitioning included prior treatment for cancer [cohort 1: HR = 3.19, 95% CI = 3.00-3.40; cohort 2: HR = 4.19, 95% CI = 3.90-4.51; cohort 3: HR = 2.07, 95% CI = 1.95-2.18] and age ≥ 75 years (cohort 1: HR = 3.04, 95% CI = 2.73-3.38; cohort 2: HR = 2.51, 95% CI = 2.17-2.89; cohort 3: HR = 1.88, 95% CI = 1.80-1.96). Females transitioned to high doses and strong opioids less rapidly than males (cohort 1: HR = 0.79, 95% CI = 0.76-0.82; cohort 2: HR = 0.70, 95% CI = 0.66-0.73; cohort 3: HR = 0.95, 95% CI = 0.93-0.96). In Australia, more than one in every 13 people initiating weak opioids transition to strong opioids. By extrapolation, more than 26 000 Australian adults initiating opioids escalate to high doses each year. People with cancer treatment history, older people and males transition to strong and high-dose opioids more rapidly than others.
Sections du résumé
BACKGROUND AND AIMS
Strong and high-dose opioids are associated with opioid overdose and death. The objective of this study was to determine the rate and predictors of transitioning to high-dose or strong opioids among people initiating opioids.
DESIGN
Retrospective cohort study.
SETTING
Australia.
PARTICIPANTS
People initiating opioid analgesics from July 2013 to January 2018 were identified from a random 10% sample of Australia's Pharmaceutical Benefits Scheme eligible population.
MEASUREMENTS
Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for the predictors of escalating to ≥ 50 mg oral morphine equivalents (OMEs)/day (cohort 1); ≥ 90 mg OMEs/day (cohort 2) and transitioning from weak opioids to strong opioids (cohort 3) over 12 months of follow-up. Predictors included age, sex, number of comorbidities, history of depression, prior treatment for cancer and selected other medication use.
FINDINGS
In total, 861 691 people initiated opioids at average doses < 50 mg OMEs/day (cohort 1), 874 401 at < 90 mg OMEs/day (cohort 2) and 603 884 initiated weak opioids (cohort 3). Overall, 1.4% of people escalated to doses ≥ 50 mg OMEs/day, 0.8% to doses ≥ 90 mg OMEs/day and 7.3% transitioned to strong opioids. The strongest predictors of transitioning included prior treatment for cancer [cohort 1: HR = 3.19, 95% CI = 3.00-3.40; cohort 2: HR = 4.19, 95% CI = 3.90-4.51; cohort 3: HR = 2.07, 95% CI = 1.95-2.18] and age ≥ 75 years (cohort 1: HR = 3.04, 95% CI = 2.73-3.38; cohort 2: HR = 2.51, 95% CI = 2.17-2.89; cohort 3: HR = 1.88, 95% CI = 1.80-1.96). Females transitioned to high doses and strong opioids less rapidly than males (cohort 1: HR = 0.79, 95% CI = 0.76-0.82; cohort 2: HR = 0.70, 95% CI = 0.66-0.73; cohort 3: HR = 0.95, 95% CI = 0.93-0.96).
CONCLUSIONS
In Australia, more than one in every 13 people initiating weak opioids transition to strong opioids. By extrapolation, more than 26 000 Australian adults initiating opioids escalate to high doses each year. People with cancer treatment history, older people and males transition to strong and high-dose opioids more rapidly than others.
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1088-1097Informations de copyright
© 2019 Society for the Study of Addiction.
Références
Opioid prescribing is still high and varies widely throughout the U.S.: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2017 [online]. Available at: https://www.cdc.gov/media/releases/2017/p0706-opioid.html (accessed 2 April 2019).
Overview of national data on opioid-related harms and deaths. Government of Canada; 2018 [online]. Available at: https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/data-surveillance-research/harms-deaths.html (accessed 1 February 2019).
Roxburgh A., Dobbins T., Degenhardt L., Peacock A. Opioid-, amphetamine-, and cocaine-induced deaths in Australia. Sydney: National Drug and Alcohol Research Centre, UNSW; 2018.
Rummans T. A., Burton M. C., Dawson N. L. How good intentions contributed to bad outcomes: the opioid crisis. Mayo Clin Proc 2018; 93: 344-350.
Boudreau D., Von Korff M., Rutter C. M., Saunders K., Ray G. T., Sullivan M. D., et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009; 18: 1166-1175.
Karanges E. A., Blanch B., Buckley N. A., Pearson S. A. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol 2016; 82: 255-267.
Gisev N., Campbell G., Lalic S., Larney S., Peacock A., Nielsen S., et al. Current opioid access, use, and problems in Australasian jurisdictions. Curr Addict Rep 2018; 5: 464-472.
Guy G. P., Zhang K., Bohm M. K., Losby J., Lewis B., Young R., et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. Morb Mortal Wkly Rep 2017; 66: 697-704.
Lalic S., Ilomaki J., Bell J. S., Korhonen M. J., Gisev N. Prevalence and incidence of prescription opioid analgesic use in Australia. Br J Clin Pharmacol 2019; 85: 202-215.
Canadian Institute for Health Information (CIHI). Pan-Canadian Trends in the Prescribing of Opioids and Benzodiazepines, 2012 to 2017. Ottawa, ON: CIHI, p. 2018.
Dasgupta N., Funk M. J., Proescholdbell S., Hirsch A., Ribisl K. M., Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med (Malden, MA) 2016; 17: 85-98.
Spooner L., Fernandes K., Martins D., Juurlink D., Mamdani M., Paterson J. M., et al. High-dose opioid prescribing and opioid-related hospitalization: a population-based study. PLOS ONE 2016; 11: e0167479.
Lalic S., Gisev N., Bell J. S., Korhonen M. J., Ilomaki J. Predictors of persistent prescription opioid analgesic use among people without cancer in Australia. Br J Clin Pharmacol 2018; 84: 1267-1278.
Dunn K. M., Saunders K. W., Rutter C. M., Banta-Green C. J., Merrill J. O., Sullivan M. D., et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152: 85-92.
Bohnert A. S., Valenstein M., Bair M. J., Ganoczy D., McCarthy J. F., Ilgen M. A., et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315-1321.
Gomes T., Redelmeier D. A., Juurlink D. N., Dhalla I. A., Camacho X., Mamdani M. M. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med 2013; 173: 196-201.
Saunders K. W., Dunn K. M., Merrill J. O., Sullivan M., Weisner C., Braden J. B., et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 2010; 25: 310-315.
Bohnert A. S., Logan J. E., Ganoczy D., Dowell D. A detailed exploration into the association of prescribed opioid dosage and overdose deaths among patients with chronic pain. Med Care 2016; 54: 435-441.
Garg R. K., Fulton-Kehoe D., Franklin G. M. Patterns of opioid use and risk of opioid overdose death among Medicaid patients. Med Care 2017; 55: 661-668.
Opioid Prescribing. Centers for Disease Control and Prevention. US Department of Health and Human Services [online]. Available at: https://www.cdc.gov/vitalsigns/opioids/infographic.html#infographic (accessed 1 February 2019).
Dowell D., Haegerich T. M., Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA 2016; 315: 1624-1645.
Busse J. W., Craigie S., Juurlink D. N., Buckley D. N., Wang L., Couban R. J., et al. Guideline for opioid therapy and chronic noncancer pain. Can Med Assoc J 2017; 189: E659-e66.
Chou R., Turner J. A., Devine E. B., Hansen R. N., Sullivan S. D., Blazina I., et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health pathways to prevention workshop. Ann Intern Med 2015; 162: 276-286.
Henry S. G., Wilsey B. L., Melnikow J., Iosif A. M. Dose escalation during the first year of long-term opioid therapy for chronic pain. Pain Med 2015; 16: 733-744.
Kaplovitch E., Gomes T., Camacho X., Dhalla I. A., Mamdani M. M., Juurlink D. N. Sex differences in dose escalation and overdose death during chronic opioid therapy: a population-based cohort study. PLOS ONE 2015; 10: e0134550.
Mellish L., Karanges E. A., Litchfield M. J., Schaffer A. L., Blanch B., Daniels B. J., et al. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes 2015; 8: 634.
Australian Statistics on Medicines 2011. Canberra: Department of Health: Australian Government; 2013 [online]. Available at: http://www.pbs.gov.au/info/statistics/asm/asm-2011 (last accessed 8 April 2019).
ATC/DDD Index 2018. WHO Collaborating Centre for Drug Statistics Methodology; 2017 [online]. Available at: https://www.whocc.no/atc_ddd_index/ (last accessed 15 February 2019).
Gisev N., Pearson S. A., Karanges E. A., Larance B., Buckley N. A., Larney S., et al. To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia? Pharmacoepidemiol Drug Saf 2018; 27: 550-555.
Drewes A. M., Jensen R. D., Nielsen L. M., Droney J., Christrup L. L., Arendt-Nielsen L., et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol 2013; 75: 60-78.
Cifuentes M., Webster B., Genevay S., Pransky G. The course of opioid prescribing for a new episode of disabling low back pain: opioid features and dose escalation. Pain 2010; 151: 22-29.
Nielsen S., Degenhardt L., Hoban B., Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf 2016; 25: 733-737.
Sun E. C., Dixit A., Humphreys K., Darnall B. D., Baker L. C., Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017; 356: j760.
Pratt N. L., Kerr M., Barratt J. D., Kemp-Casey A., Kalisch Ellett L. M., Ramsay E., et al. The validity of the Rx-risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system. BMJ Open 2018; 8: e021122.
Lu C. Y., Barratt J., Vitry A., Roughead E. Charlson and Rx-risk comorbidity indices were predictive of mortality in the Australian health care setting. J Clin Epidemiol 2011; 64: 223-228.
Webster L. R. Risk factors for opioid-use disorder and overdose. Anesth Analg 2017; 125: 1741-1748.
Weimer M. B., Hartung D. M., Ahmed S., Nicolaidis C. A chronic opioid therapy dose reduction policy in primary care. Subst Abuse 2016; 37: 141-147.
McCrorie C., Closs S. J., House A., Petty D., Ziegler L., Glidewell L., et al. Understanding long-term opioid prescribing for non-cancer pain in primary care: a qualitative study. BMC Fam Pract 2015; 16: 121.
Naples J. G., Gellad W. F., Hanlon J. T. The role of opioid analgesics in geriatric pain management. Clin Geriatr Med 2016; 32: 725-735.
Chau D. L., Walker V., Pai L., Cho L. M. Opiates and elderly: use and side effects. Clin Interv Aging 2008; 3: 273-278.
Rolita L., Spegman A., Tang X., Cronstein B. N. Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults. J Am Geriatr Soc 2013; 61: 335-340.
Scott J. C., Stanski D. R. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240: 159-166.
Mercadante S., Ferrera P., Villari P., Casuccio A. Opioid escalation in patients with cancer pain: the effect of age. J Pain Symptom Manage 2006; 32: 413-419.
Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer 1998; 34: 627-631.
WHO's cancer pain ladder for adults. World Health Organization; 2018 [online]. Available at: http://www.who.int/cancer/palliative/painladder/en/ (accessed 1 February 2019).
Bandieri E., Romero M., Ripamonti C. I., Artioli F., Sichetti D., Fanizza C., et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 2016; 34: 436-442.
Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 2010; 56: 514-517; e202-5.
Gomes T., Juurlink D. N., Dhalla I. A., Mailis-Gagnon A., Paterson J. M., Mamdani M. M. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011; 5: e13-e22.
Sullivan M. D., Ballantyne J. C. Must we reduce pain intensity to treat chronic pain? Pain 2016; 157: 65-69.